Blog
RSS FeedPosted by Michael Wonder on 17 Jun 2026
Biogen Canada disappointed by outcome of pan-Canadian Pharmaceutical Alliance negotiations for Skyclarys
16 June 2026 - - Biogen Canada is disappointed that negotiations with the pan-Canadian Pharmaceutical Alliance for Skyclarys (omaveloxolone) have ...
Posted by Michael Wonder on 11 Jun 2026
Eli Lilly Canada welcome Quebec public reimbursement of Verzenio (abemaciclib) for mBC following successful PCPA negotiation
10 June 2026 - Eli Lilly Canada is pleased to announce that Verzenio (abemaciclib) is now publicly reimbursed in Québec ...
Posted by Michael Wonder on 09 Jun 2026
New progress toward public reimbursement of Skyclarys for people living with Friedreich ataxia in Quebec
8 June 2026 - Biogen is pleased to announce a positive outcome from the Institut national d'excellence en santé et en ...
Posted by Michael Wonder on 29 May 2026
BeOne Medicines receives positive reimbursement recommendations from CDA-AMC and INESSS for Tevimbra in first-line nasopharyngeal carcinoma
28 May 2026 - BeOne Medicines today announced that Canada's Drug Agency and the Institut national d'excellence en santé et ...
Posted by Michael Wonder on 27 May 2026
Pfizer's Braftovi becomes first Pfizer therapy to receive priority access under Ontario's FAST program, accelerating treatment for Canadians with metastatic colorectal cancer
26 May 2026 - Pfizer Canada announces that Braftovi (encorafenib) will be funded under Ontario's Funding Accelerated for Specific Treatments ...
Posted by Michael Wonder on 24 May 2026
Gazyva (obinutuzumab) receives positive reimbursement recommendation from Canada's Drug Agency (CDA-AMC) for adults with active lupus nephritis
22 May 2026 - Roche Canada is pleased to share that on 6 May 2026, Canada's Drug Agency recommended Gazyva ...
Posted by Michael Wonder on 08 Apr 2026
Cancer clinicians call for three actions Canada's health systems should take to improve cancer care
7 April 2026 - April Cancer Awareness Month a good time for concrete action ...
Posted by Michael Wonder on 18 Mar 2026
When generic versions of weight loss drugs arrive, public plans should cover them, experts say
17 March 2026 - When Bonnie Evoy entered her mid 60s, she unexpectedly and rapidly gained weight. She tried for ...
Posted by Michael Wonder on 03 Mar 2026
Alnylam receives positive recommendation from Canada's Drug Agency for the public reimbursement of Amvuttra (vutrisiran injection), the first and only RNAi therapeutic for the treatment of cardiomyopathy in adult patients with ATTR amyloidosis
2 March 2026 - Alnylam Canada is pleased to announce it has received a positive recommendation from Canada's Drug Agency for ...
Posted by Michael Wonder on 28 Feb 2026
Ontario becomes the first province to publicly reimburse the first targeted oral therapy for adults with grade 2 IDH-mutant glioma
27 February 2026 - Servier Canada announces Ontario coverage of Voranigo under the FAST program. ...
Posted by Michael Wonder on 21 Feb 2026
Canada's public drug plans shouldn't cover new Alzheimer's drug, agency says
19 February 2026 - Lecanemab, also known as Leqembi, is approved to treat mild cognitive impairment, early Alzheimer's. ...
Posted by Michael Wonder on 11 Feb 2026
Canadians wait, on average, more than 65 weeks longer for access to new medicines than Europeans and 90 weeks more than Americans
10 February 2025 - Canadian patients are waiting, on average, more than 65 weeks longer than Europeans and over 90 ...
Posted by Michael Wonder on 07 Feb 2026
Kisqali receives positive draft recommendation from Canada's Drug Agency for all eligible early breast cancer patients at high risk of recurrence
6 February 2026 - The draft recommendation for Kisqali (ribociclib tablets) from Canada's Drug Agency (CDA-AMC) supports public reimbursement for hormone ...
Posted by Michael Wonder on 04 Feb 2026
Rezurock now reimbursed in Ontario and British Columbia for people living with chronic graft versus host disease
3 February 2026 - British Columbia and Ontario recently added Rezurock (belumosudil) to their provincial formularies for adult and pediatric patients ...
Posted by Michael Wonder on 04 Feb 2026
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer
3 February 2026 - GSK announced today that Quebec has become the first Canadian province to publicly reimburse Jemperli (dostarlimab for ...